Member Info for GLTader

Interesting to note more new vacancies in YGEN website in manufacturing.

Well, you only replace / add to these roles if sales demands them.......

I am not a trader and invested here as I believe it is undervalued - not selling anything below £1.42.

But if you were, I suggest you look at the AT of 2,000 shares each go which started this week's rally on Monday. I suspect there is an order in the background being worked.

The recent upsurge in China, but also globally, of RSV is supporting sentiments. But I think it is simply a re-rating post YGEN acquisition and potential news on settlement, commercial contract, etc

WBAFC, today's rise has nothing to do with swine flu, although it and the China outbreak of RSV, is a reminder of the need for good, easily accessible diagnostics. I think, and am confident, it is one of the three I cited below.

This could be either:

(a) settlement with DHSC news expected;

(b) unsolicited takeover bid;

(c) mega commercial contract.

As said, this should be north of £1 before any of above even......

PI100, who knows what will be re China current outbreak.......

.....but the key is that we (the world and not just China) need comprehensive testing and diagnostics to prevent or get ahead of another Covid pandemic - and I suggest you read Novacyt's product offering.

Getting reported more....

https://www.nationalheraldindia.com/international/china-sees-undiagnosed-pneumonia-outbreak-in-children-report

And yes, humankind should heed lessons from 4 years ago. We are more prepared with diagnostics and hopefully treatment.

DHSC - get the case settled and partner with Novacyt and others to prevent another issue.

Dazzerman, I think we will get a settlement before an acquisition. But, that's just my view.

For now, the growth potential within YGEN portfolio AND the soon to be launched Novacyt products, should keep the company busy.

Wow - this is one I was looking out for whilst at Yourgene. I had suspected they could be the Yourgene buyer (rather than Novacyt). Great news!

Won't be more acquisitions. Could be contract news or even settlement!

Lyn's first order of business when he joined Yourgene, which he did do successfully, was settlement with Illumina and then restructure of Thermofisher loan.

Thanks to Kaeren for more information on the matter. I think any settlement at NIL or anything above NIL in favour of Novacyt will take us above £1.20 easily.

Thank you Kaeren - very informative read. I am even more convinced now a settlement will be reached prior to court hearing date.

Bring on the contracts and settlements!

You were right before Dazzerman, so hope you are right again!

There was a very significant contract being negotiated on Ranger I recall before the equity raise and T/O, so perhaps now, with clarity of YGEN future, the contracts will start rolling in.......

Today, Novacyt is a £25m T/O business, growing at circa 20% or more, with GP% of circa 55-60%, backed up with a circa £50m cash balance by end of this year. So, based on that alone, we are (significantly) undervalued.

The DHSC dispute is creating an uncertainty but other than a settlement, nothing will happen on that between now and June 2024, and even then outcome not known or may be appealed. If there is a settlement between now and June 2024, then I see that as a big positive for the SP.

We can definitely expect more corporate development news, brokers updates, commercial news etc, so I am hopeful we will be trending upwards from here until mid-next year, when people can take a view......if not settled by then.

Shame that quite a few of you are looking backwards, rather than forwards.

All whilst, I am sure, those enjoying Yourgene products and know of its potential, will be.

Try to remember, Novacyt today is a circa £25m TO business, with 55% GP and a large IP portfolio and a footprint globally. The Novacyt of old is no longer other than the DHSC dispute which will hopefully clear in due course.

PI100, Novacyt is a very different company today versus before September. As I mentioned before, it is now a £25m revenue business with GP 55%, and a large IP portfolio.

Sadly, it is still saddled with legacy (ie experiences / expectations like yours) but that will wane. Quite a few institutions backed Yourgene, and I see one of objectives of the acquisition is to attract institutional investors. So, I see an uptrend from here, albeit with the yo-yo's due to legacy referred to above. So long, it's an uptrend, I am happy......

Hi Frawdo,

All good questions. Based on what I know:

1. Yes, 2m new cancer patient per annum. So, when I did a quick estimate of future potential, I said 10% which I believe can be achieved.

2 & 3. Good research. I used $100 per test based on selling price of our test to hospitals / clinics etc. They will charge more of course for their own overheads and profits. So, $450 per test seems right, cheap I would say given what it can prevent. They will all be reimbursable by govt / insurance where applicable.

4. DYPD already a $1m+ product within YGEN prior to Novacyt acquisition. The EU certification, first of its kind, will simply (a) accelerate the adoption and growth, (b) place Novacyt DYPD test as the defacto and (c) likely increase coverage.

I should add that US has been slower than Europe in adopting this BUT has already begun doing so. Yourgene has submissions into regulatory framework there already. I think that is coming imminently too. Sales already started but with approval, you can imagine its growth.

Re competition, I wouldn't worry. There is room for others and it will help adoption. YGEN / Novacyt test being the leader is the key and if we can get 10% (or more) of the marketplace, that's a huge ARR.

Finally, I just wanted to add that Lyn Rees, whatever people may think, does put his money where his mouth is. So, I am 99% confident there will be directors' buys. Watch out for that. But given Novacyt relatively smaller share capital, it may be an order being executed.......

This is a very good RNS - the first conformity of its kind.

At say $100/test and 10% market share (conservative), we are looking at $20m annual revenue.

Just DPYD is probably worth the entire acquisition price.

Add to that NIPT and Ranger technology which is applicable across multi sector......

PI100, Yourgene core business (ie ex-Covid) is growing 20%+. I also believe Novacyt pf will do the same when new products come into play as we turn the year. Along with cross-fertilisation of customer base, we should beat that really.

CS, P100, I sympathise with your sentiments. But Novacyt today post Yourgene acquisition is a completely different company to the one before. Where you had £5-6m revenue (ex-Covid), it is now £25m, and growing 20%+. For all their sins, the management team is also expanded. Customer base has grown and product portfolio enhanced.

Look forward, not back.

Perhaps we are getting closer to a settlement......

Perhaps there are institutional investors nibbling (moving from Yourgene base).....

Perhaps there are new commercial contracts being negotiated.....

Or perhaps it's just market waking up to the fact it has circa £50m cash + a business with revenue of circa £25m today....

Whatever it is, still undervalued and about 70p more to £1.20, which I think is where this should be.